Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Int J Mol Sci ; 22(7)2021 Mar 27.
Artículo en Inglés | MEDLINE | ID: mdl-33801783

RESUMEN

The present study investigated expression of endogenous interleukin-13 (IL-13) and its possible function in the hippocampus of prothrombin kringle-2 (pKr-2)-lesioned rats. Here we report that intrahippocampal injection of pKr-2 revealed a significant loss of NeuN-immunopositive (NeuN+) and Nissl+ cells in the hippocampus at 7 days after pKr-2. In parallel, pKr-2 increased IL-13 levels, which reached a peak at 3 days post pKr-2 and sustained up to 7 days post pKr-2. IL-13 immunoreactivity was seen exclusively in activated microglia/macrophages and neutrophils, but not in neurons or astrocytes. In experiments designed to explore the involvement of IL-13 in neurodegeneration, IL-13 neutralizing antibody (IL-13Nab) significantly increased survival of NeuN+ and Nissl+ cells. Accompanying neuroprotection, immunohistochemical analysis indicated that IL-13Nab inhibited pKr-2-induced expression of inducible nitric oxide synthase and myeloperoxidase within activated microglia/macrophages and neutrophils, possibly resulting in attenuation of reactive oxygen species (ROS) generation and oxidative damage of DNA and protein. The current findings suggest that the endogenous IL-13 expressed in pKr-2 activated microglia/macrophages and neutrophils might be harmful to hippocampal neurons via oxidative stress.


Asunto(s)
Hipocampo/metabolismo , Interleucina-13/fisiología , Estrés Oxidativo , Protrombina/química , Animales , Astrocitos/metabolismo , Daño del ADN , Femenino , Hipocampo/efectos de los fármacos , Kringles , Macrófagos/metabolismo , Microglía/metabolismo , Neuronas/metabolismo , Neutrófilos/metabolismo , Oxígeno/química , Dominios Proteicos , Ratas , Ratas Sprague-Dawley
2.
J Immunol Res ; 2020: 5093493, 2020.
Artículo en Inglés | MEDLINE | ID: mdl-33062722

RESUMEN

The present study examined whether crosstalk between cannabinoid (CB) and transient potential receptor vanilloid type 1 (TRPV1) could contribute to the survival of nigrostriatal dopamine neurons in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease (PD). MPTP induced a significant loss of nigrostriatal dopamine neurons and glial activation in the substantia nigra (SN) and striatum (STR) as visualized by tyrosine hydroxylase (TH) or macrophage antigen complex-1 (MAC-1) or glial fibrillary acidic protein (GFAP) immunocytochemistry, respectively. RT-PCR analysis shows the upregulation of inducible nitric oxide synthase, interleukin-1ß, and tumor necrosis factor-α in microglia in the SN in vivo, indicating the activation of the inflammatory system. By contrast, treatment with capsaicin (a specific TRPV1 agonist) increased the survival of dopamine neurons in the SN and their fibers and dopamine levels in the STR in MPTP mice. Capsaicin neuroprotection is accompanied by inhibiting MPTP-induced glial activation and production of inflammatory cytokines. Treatment with AM251 and AM630 (CB1/2 antagonists) abolished capsaicin-induced beneficial effects, indicating the existence of a functional crosstalk between CB and TRPV1. Moreover, treatment with anandamide (an endogenous agonist for both CB and TRVP1) rescued nigrostriatal dopamine neurons and reduced gliosis-derived neuroinflammatory responses in MPTP mice. These results suggest that the cannabinoid and vanilloid system may be beneficial for the treatment of neurodegenerative diseases, such as PD, that are associated with neuroinflammation.


Asunto(s)
Neuronas Dopaminérgicas/fisiología , Neuroglía/patología , Enfermedad de Parkinson/metabolismo , Receptores de Cannabinoides/metabolismo , Sustancia Negra/patología , Canales Catiónicos TRPV/metabolismo , 1-Metil-4-fenil-1,2,3,6-Tetrahidropiridina , Animales , Capsaicina/metabolismo , Modelos Animales de Enfermedad , Humanos , Indoles/metabolismo , Ratones , Ratones Endogámicos C57BL , Inflamación Neurogénica , Neuroprotección , Piperidinas/metabolismo , Pirazoles/metabolismo , Receptor Cross-Talk
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...